Viatris Free Cash Flow 2010-2024 | VTRS

Viatris free cash flow for the twelve months ending September 30, 2024 was , a year-over-year.

  • Viatris annual free cash flow for 2023 was $2.437B, a 4.84% decline from 2022.
  • Viatris annual free cash flow for 2022 was $2.56B, a 0.68% decline from 2021.
  • Viatris annual free cash flow for 2021 was $2.578B, a 160.17% increase from 2020.

Viatris Free Cash Flow 2010-2024 | VTRS

  • Viatris annual free cash flow for 2023 was $2.437B, a 4.84% decline from 2022.
  • Viatris annual free cash flow for 2022 was $2.56B, a 0.68% decline from 2021.
  • Viatris annual free cash flow for 2021 was $2.578B, a 160.17% increase from 2020.
Related Stocks
Company NameMarket
Cap
Elevance Health (ELV)$85B
Cencora (COR)$43.7B
DiDi Global (DIDIY)$22.9B
Natera (NTRA)$20.9B
ICON (ICLR)$16.9B
Avantor (AVTR)$14.3B
Revvity (RVTY)$13.5B
BioMerieux (BMXMF)$12.7B
CochLear (CHEOY)$11.8B
Solventum (SOLV)$11.5B
Medpace Holdings (MEDP)$10.4B
Doximity (DOCS)$10.3B
Charles River Laboratories (CRL)$9.3B
HealthEquity (HQY)$8.2B
Sonic Healthcare (SKHHY)$8.2B
Bausch + Lomb (BLCO)$6.3B
Amplifon S.p.A (AMFPF)$5.9B
Sotera Health (SHC)$3.8B
Organon (OGN)$3.7B
BrightSpring Health Services (BTSG)$3B
Surgery Partners (SGRY)$2.5B
Concentras Parent (CON)$2.5B
Ardent Health Partners (ARDT)$2.3B
GeneDx Holdings (WGS)$2.1B
Premier (PINC)$2.1B
PACS (PACS)$2B
Alignment Healthcare (ALHC)$2B
Ryman Healthcare (RYHTY)$1.7B
GoodRx Holdings (GDRX)$1.7B
Teladoc Health (TDOC)$1.5B